AI Terminal
NFL Biosciences
Report Publication Announcement • Jan 9, 2024
1553_iss_2024-01-09_0e98dc18-dede-4a41-b0aa-52f431274c26.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
NFL BIOSCIENCES: FINANCIAL CALENDAR FOR 2024
NFL BIOSCIENCES (Euronext Growth Paris - FR0014003XT0 - ALNFL), a biopharmaceutical company developing botanical drugs for the treatment of addictions, presents its financial communication calendar for 2024.
| Subject | Date* |
|---|---|
| 2023 annual results | March 29th 2024 |
| Annual General Meeting (Montpellier) | May 30th 2024 |
| 2024 half-year results | September 27th 2024 |
*Press releases will be published after the close of the stock market
The calendar is provided for information purposes only and may be subject to modification
About NFL Biosciences
NFL Biosciences is a biopharmaceutical company based in the Montpellier area which drug candidates for the treatment of addictions. NFL Biosciences' ambition is to bring new, natural, safer and more effective therapeutic solutions to the entire world population, including low- and middle-income countries. Its most advanced product, called NFL-101, is a standardized, nicotine free tobacco leaf extract protected by two patent families. NFL Biosciences intends who want to quit a natural, safe, easy-to-administer and personalized alternative. NFL-Biosciences is also developing NFL-301, a natural drug candidate for the reduction of alcohol consumption and has a drug development project for the treatment of cannabis use disorder.
The shares of NFL Biosciences are listed on Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at www.nflbiosciences.com
Contacts
Bruno Lafont – [email protected] - 04 11 93 76 67
Agence Calyptus - [email protected] - 01 53 65 68 68